NEW YORK (GenomeWeb News) – Microfluidics firm Dolomite today said it has licensed microdroplet generation technology IP from the Japan Science and Technology Agency.

The deal covers patent families WO2002/068104 and WO2005/089921, and as part of the agreement, Dolomite can sublicense the technology. Licenses are issued on a per-chip basis and are available in any quantity. Dolomite customers can purchase and use Dolomite droplet chips for R&D.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Aug
20
Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.